Short-course radiotherapy followed by penpulimab plus CAPEOX before surgery for microsatellite-stable locally advanced rectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2 neoadjuvant trial that gives participants short-course radiotherapy (SCRT) followed by sequential penpulimab combined with CAPEOX chemotherapy prior to clinical restaging. After neoadjuvant therapy, patients undergo imaging and clinical reassessment to determine whether they can pursue a watch-and-wait approach or should proceed to radical (TME) surgery. The trial collects safety and efficacy data, including tumor response and surgical outcomes. The goal is to see if adding immunotherapy to SCRT and chemotherapy improves preoperative tumor control in MSS rectal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed consent
* 18 years \< age ≤ 75 years
* ECOG score is 0-1
* Patients with pathologically confirmed rectal adenocarcinoma, assessed by MRI as mid-low rectal cancer (the lower border of the tumor is less than 10cm from the anal verge), clinical stage II-III (cT1-2N1-2M0 or T3-4N0-2M0) according to the 8th Edition of AJCC Cancer Staging Manual
* Without emergency operation due to complication (bleeding, perforation or obstruction) caused by rectal cancer
* Microsatellite Instability detection using PCR capillary electrophoresis results in MSS
* Without any anti-tumor treatment
* No distant metastasis
* Have an imaging measurable or clinically assessable lesion
* Adequate organ and bone marrow function
* Female participants of childbearing age or male participants whose sexual partners are women of childbearing age are required to use effective contraception for the entire treatment period and for 6 months after the end of the treatment period

Exclusion Criteria:

* Recurrent rectal cancer
* Previous treatment with pelvic radiotherapy, rectal cancer surgery, chemotherapy, targeted therapy, immune checkpoint inhibitors (including but not limited to PD-1, PD-L1, CTLA-4)
* Proven inability to receive radiotherapy or allergy to the components of Penpulimab, capecitabine, oxaliplatin or their excipients
* Intestinal obstruction due to tumor (except in patients who have received a stoma)
* History of other primary malignancies, except for: malignancies in complete remission for at least 2 years prior to enrolment and not requiring other treatment during the study period; adequately treated non-melanoma skin cancer or lentigo maligna with no evidence of disease recurrence; adequately treated carcinoma in situ with no evidence of disease recurrence
* Active, known or suspected autoimmune disease or history of this disease within the previous 2 years (patients with vitiligo, psoriasis, alopecia or Graves' disease not requiring systemic treatment within the last 2 years, hypothyroidism requiring only thyroid hormone replacement therapy and type I diabetes requiring only insulin replacement therapy may be enrolled)
* Any of the following within 6 months prior to the start of treatment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association classification II-IV), cerebrovascular event, transient ischaemic attack, severe arrhythmia requiring drug treatment or symptomatic pulmonary embolism
* History of allogeneic organ transplantation and allogeneic haematopoietic stem cell transplantation
* Uncontrolled comorbidities including but not limited to: HIV infected; Serious infections that are active or poorly controlled clinically
* Pregnant woman or lactating woman
* Patients who have participated in another drug clinical trial within 4 weeks
* Suffering from acute or chronic active hepatitis B (HBsAg-positive and HBV DNA ≥ 200 IU/mL or ≥ 103 copies/mL) or acute or chronic active hepatitis C (HCV-positive and HCV RNA-positive)
* Received live attenuated vaccine within 4 weeks prior to enrolment or planned during the study period
* Major surgical procedure within 4 weeks prior to enrolment
* History of interstitial pneumonia
* Other acute or chronic diseases, mental disorders, or laboratory test abnormalities that may result in: increasing the risk associated with research participation or drug administration, or interfering with the interpretation of the results of the study, and the patient was classified as not eligible to participate in this study according to the judgment of the researchers

Where it's running

• Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
  Shanghai, None Selected, China Recruiting

Study contacts

• Principal investigator: Ren Zhao, MD, PHD — Ruijin Hospitlal , Shanghai Jiaotong University School of Medicine
• Study coordinator: Ren Zhao, MD, PHD
• Email: zhaorensurgeon@aliyun.com
• Phone: +8618917762018

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs. double stapling and purse-string techniques after rectal cancer surgery

  This trial tests whether using a single-stapling method to join the bowel after rectal cancer surgery results in fewer leaks compared with the double-stapling method.

  Recruiting Alexandria University · Alexandria · NCT07929415

• DEM301 in advanced colorectal cancer: a first-in-human test

  This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.

  Recruiting at 2 sites Phase 1 DEM BioPharma, Inc. · Birtinya, Queensland and 1 other locations · NCT07805369

• Rectal cancer registry to track real-world treatments and outcomes

  This registry collects real-world data on how locally advanced rectal cancer is treated in Austria, to see how TNT and dMMR/MSI-H cases are managed and what outcomes occur.

  Recruiting at 2 sites Austrian Breast & Colorectal Cancer Study Group · Wiener Neustadt, Lower Austria and 5 other locations · NCT07780305

• Aerobic exercise and guided imagery for bowel problems after rectal cancer surgery

  This study tests whether a program of aerobic exercise plus guided imagery helps people with low anterior resection syndrome after rectal cancer surgery.

  Recruiting Biruni University · Istanbul · NCT07732894

• Active surveillance vs chemoradiotherapy after local removal of intermediate-risk T1 rectal cancer

  This study tests whether close follow-up alone after local removal of early rectal cancer can match the cancer control of adding chemoradiotherapy, while reducing treatment-related side effects.

  Recruiting at 2 sites Medical University of Gdansk · Limoges and 2 other locations · NCT07669298

• Different-Dose Short-Course Radiotherapy With CAPOX, PD-1 Blockade, and IL-2 in Locally Advanced Rectal Cancer

  This phase II trial tests whether a low-dose short-course radiotherapy combined with CAPOX, a PD-1 blocker, and IL-2 works as well as the standard-dose short-course approach in patients with locally advanced rectal cancer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07646639

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.